Canadian Cancer Trials Group Bulletins


Recent Publications

Canadian Cancer Trials Group MA.9

Albain KS, Barlow WE, Ravdin PM, Farrar WB, Burton GV, Ketchel SJ, Cobau CD, Levine EG, Ingle JN, Pritchard KI, Lichter AS, Schneider DJ, Abeloff MD, Henderson IC, Muss HB, Green SJ, Lew D, Livingston RB, Martino S, Osborne CK, for The Breast Cancer Intergroup of North America. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. The Lancet 374: 2055-63, 2009.

Canadian Agency for Drugs and Technology in Health

Mittmann N., Evans W.K., Rocchi A., Longo C. J., Au H.J., Husereau D., Leighl N., Isogai P., Krahn M., Peacock S., Marshall D., Coyle D., Malfair Taylor S.C., Jacobs P., Oh P.I. Addendum to CADTH's Guidelines for the Economic Evaluation of Health Technologies: Specific Guidance for Oncology Products. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2009.

Association Between DFS and OS in Colon Cancer Patients when Survival is Prolonged After Recurrence

de Gramont A, Hubbard J, Shi Q, O'Connell MJ, Buyse M, Benedetti J, Bot B, O'Callaghan C, Yothers G, Goldberg RM, Blanke CD, Benson A, Deng Q, Alberts SR, Andre T, Wolmark N, Grothey A, Sargent D. Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set (ONLINE). J Clin Oncol 2009.